1
|
Arbelaez-Camargo D, Roig-Carreras M, García-Montoya E, Pérez-Lozano P, Miñarro-Carmona M, Ticó-Grau JR, Suñé-Negre JM. Osmolality predictive models of different polymers as tools in parenteral and ophthalmic formulation development. Int J Pharm 2018; 543:190-200. [PMID: 29604368 DOI: 10.1016/j.ijpharm.2018.03.052] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2017] [Revised: 03/23/2018] [Accepted: 03/27/2018] [Indexed: 12/20/2022]
Abstract
During the development of parenteral dosage forms, different physicochemical studies are required to ensure stable, effective and safe formulations. The osmolality of this kind of dosage forms should bear a close similarity to the body fluids to prevent local irritation, pain or even more significant side effects like endothelial damage. The osmotic studies performed in Polyethylene glycol 400 (PEG 400), Polyethylene glycol 4000 (PEG 4000), Poloxamer 407 (P407), Sodium Hyaluronate (SH), Chondroitin Sulphate Sodium (CS), Cremophor RH 40 (CRE40) and Polyvinyl alcohol (PVA) aqueous solutions, showed that the theoretical determination of the osmolality based on their molecular weight as the only determinant factor did not agree with the values obtained by the measurement of colligative properties such as the freezing point depression. The data obtained from this study and its analysis, provided predictive equations that can be used as tools in the primary development to estimate formulation's osmolality at different concentrations; and its evolution over a period at the hypothetical worst-case scenario of storage temperature.
Collapse
Affiliation(s)
- Diana Arbelaez-Camargo
- Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, University of Barcelona, Joan XXIII 27-32, CP 08028 Barcelona, Spain.
| | - Manel Roig-Carreras
- Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, University of Barcelona, Joan XXIII 27-32, CP 08028 Barcelona, Spain
| | - Encarna García-Montoya
- Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, University of Barcelona, Joan XXIII 27-32, CP 08028 Barcelona, Spain; Pharmacotherapy, Pharmacogenetics and Pharmaceutical Technology Research Group, IDIBELL-UB, Duran i Reynals Hospital, 3a level, Gran Via de l'Hospitalet 199, CP 08908 Hospitalet de Llobregat, Barcelona, Spain.
| | - Pilar Pérez-Lozano
- Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, University of Barcelona, Joan XXIII 27-32, CP 08028 Barcelona, Spain; Pharmacotherapy, Pharmacogenetics and Pharmaceutical Technology Research Group, IDIBELL-UB, Duran i Reynals Hospital, 3a level, Gran Via de l'Hospitalet 199, CP 08908 Hospitalet de Llobregat, Barcelona, Spain
| | - Montserrat Miñarro-Carmona
- Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, University of Barcelona, Joan XXIII 27-32, CP 08028 Barcelona, Spain; Pharmacotherapy, Pharmacogenetics and Pharmaceutical Technology Research Group, IDIBELL-UB, Duran i Reynals Hospital, 3a level, Gran Via de l'Hospitalet 199, CP 08908 Hospitalet de Llobregat, Barcelona, Spain
| | - Josep Ramon Ticó-Grau
- Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, University of Barcelona, Joan XXIII 27-32, CP 08028 Barcelona, Spain; Pharmacotherapy, Pharmacogenetics and Pharmaceutical Technology Research Group, IDIBELL-UB, Duran i Reynals Hospital, 3a level, Gran Via de l'Hospitalet 199, CP 08908 Hospitalet de Llobregat, Barcelona, Spain
| | - Josep Maria Suñé-Negre
- Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, University of Barcelona, Joan XXIII 27-32, CP 08028 Barcelona, Spain; Pharmacotherapy, Pharmacogenetics and Pharmaceutical Technology Research Group, IDIBELL-UB, Duran i Reynals Hospital, 3a level, Gran Via de l'Hospitalet 199, CP 08908 Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|